Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration ...
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Hims & Hers faces new headwinds in its weight management segment with the Food and Drug Administration ending the shortage of ...
Stock in Hims & Hers Health was bound to tumble once it [could no longer sell]( ...
Hims & Hers dipped 19% post-Q4 earnings. Read here for HIMS stock's growth trends, margin concerns, and why this could be a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback